ARGX ArGEN-X SE

argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session

argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session
EN
05/10/2020

Underlying

ARGXArGEN-X SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ArGEN-X SE

Jacob Mekhael
  • Jacob Mekhael
ARGX ARGEN-X SE

argenx FIRST LOOK: ARGX-119 Ph1b shows POC in CMS, Ph3 in preparation

argenx announced its plan to advance the clinical development of ARGX-119 (muscle-specific kinase [MuSK] agonist antibody) to a registrational study in patients with congenital myasthenic syndromes (CMS) following the analysis of topline data from the phase 1b study, which showed consistent improvements through the 12-week study across multiple efficacy scores. This marks the 3rd candidate to advance to phase 3 from argenx' internal pipeline, which in our view supports the company's future growt...

10h / 9m 10h / 9m 1 EN
Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Thomas Couvreur
LEAS LEASINVEST REAL ESTATE SCA
RET RETAIL ESTATES NV
AGFB AGFA-GEVAERT NV
ARGX ARGEN-X SE
FUR FUGRO NV
10h / 12m 10h / 12m 1 EN
 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx Advances Clinical Development of ARGX-119 in Congenital Myasthe...

argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative discovery model June 30, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of p...

12h / 16m 1 EN
Jacob Mekhael
  • Jacob Mekhael
ARGX ARGEN-X SE

argenx European Commission approves Vyvgart SC in CIDP

argenx announced that the European Commission (EC) approved Vyvgart SC for the treatment of adults with progressive or relapsing active CIDP after prior treatment with corticosteroids or immunoglobulins, which comes in line with expectations following the positive CHMP opinion issued in April 2025. We anticipate a steady country by country EU launch, and continue to expect the US to remain the main driver for Vyvgart's commercial launch. We currently estimate approx. $ 1.1bn in peak sales for CI...

06/23/25 June 23, 2025 1 EN
Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Wim Lewi
GLPG GALAPAGOS NV
ARGX ARGEN-X SE
HYL HYLORIS PHARMACEUTICALS
06/23/25 June 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch